Evercore ISI raised the firm’s price target on Astria Therapeutics (ATXS) to $26 from $25 and keeps an Outperform rating on the shares. The analyst, who is adding Astria to Evercore ISI’s Core SMID List, has “high conviction” in the firm’s base case for Phase 3 HAE data due in early 2027. The firm’s scenario analysis for that data yields bull, base and bear case stock targets of $47, $26 and $6, respectively, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATXS:
- Buy Rating for Astria Therapeutics: Promising Clinical Data and Market Advantages of STAR-0310
- Promising Potential of Astria Therapeutics’ STAR-0310 in Atopic Dermatitis: Analyst Recommends Buy
- Astria Therapeutics price target raised to $20 from $16 at H.C. Wainwright
- Astria delivers on all objectives in STAR-0310 trial, says Cantor Fitzgerald
- Astria Therapeutics announces initial results from STAR-0310 trial